Biocon Biologics, Yoshindo launch Ustekinumab biosimilar in Japan EP News Bureau May 21, 2025 Ustekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis (PsA)
Biocon Biologics outlicenses two biosimilar assets to Yoshindo for commercialisation in Japan EP News Bureau Oct 17, 2022 bUstekinumab and bDenosumab to address market opportunity of approximately $700 million
